Director/PDMR Shareholding

RNS Number : 4342M

AstraZeneca PLC

28 July 2017

 

28 July 2017 11:00 BST

TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 27 July 2017, it was notified by Nazneen Rahman, a Non-Executive Director of the Company, that, on 27 July 2017, Professor Rahman purchased 500 Ordinary Shares of $0.25 each in the Company (Shares) at an aggregate price of 4338.186 pence per Share.

The Company also announces that, on 27 July 2017, it was notified by Philip Broadley, a Non-Executive Director of the Company, that, on 27 July 2017, Mr Broadley purchased 2,300 Shares at a price of 4282 pence per Share.

The attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further detail.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nazneen Rahman
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) 4335.4837 pence 461 4370.1282 pence 39
d)	Aggregated information - Aggregated volume - Price	500 4338.1860 pence
e)	Date of the transaction	27 July 2017
f)	Place of the transaction	XLON

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Philip Broadley
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) 4282 pence 2,300
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	27 July 2017
f)	Place of the transaction	XLON

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Esra Erkal-Paler	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Karen Birmingham	UK/Global	[phone]
Matt Kent	UK/Global	[phone]
Jacob Lund	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Craig Marks	Finance, Fixed Income, M&A	[phone]
Henry Wheeler	Oncology	[phone]
Mitchell Chan	Oncology	[phone]
Lindsey Trickett	Cardiovascular & Metabolic Diseases (CVMD)	[phone]
Nick Stone	Respiratory	[phone]
Christer Gruvris	Autoimmunity, Neuroscience & Infection	[phone]
US toll free		[phone]

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

END

 

 

DSHUWSKRBNABURR